Hematopoietic Stem Cell Transplantation Market
Hematopoietic Stem Cell Transplantation Market Infographics

Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT) administers healthy hematopoietic stem cells (HSC) to patients with defective or depleted bone marrow. This improves bone marrow function and, depending on the disease being treated, leads to either the destruction of malignant tumor cells or the generation of functional cells that can replace the dysfunctional ones, as in the case of immune-deficiency syndromes, hemoglobinopathies, and other diseases.


Hematopoietic Stem Cell Transplantation Epidemiology Segmentation in the 7MM


  • Total Cases of Hematopoietic Stem Cell Transplantation
  • Type-specific Cases of Hematopoietic Stem Cell Transplantation
  • Total Cases of Hematopoietic Stem Cell Transplantation (HSCT) by Indications


Hematopoietic Stem Cell Transplantation Epidemiological Insights Observed in the 7MM (2021)

  • The total number of incident cases of Hematopoietic Stem Cell Transplantation observed in the 7MM was observed to be 56K in the year 2021
  • The highest diagnosed Hematopoietic Stem Cell Transplantation population accounting for 24K cases, was found in the United States, followed by EU5 (26K) and Japan (6K) in the year 2021. 


Hematopoietic Stem Cell Transplantation Market Insight

The market size of Hematopoietic Stem Cell Transplantation in the 7MM was found to be approximately USD 763 million in 2021.


Hematopoietic Stem Cell Transplantation Market Strengths

HSCT is a widely accepted therapeutic modality for several malignant, hematologic, immunologic, and genetic diseases. This therapy consists of the intravenous infusion of hematopoietic progenitor cells to reestablish marrow function in patients with damaged or defective bone marrow.


Hematopoietic Stem Cell Transplantation Market Opportunities

Improved outcomes of HSCT are due to improvements in tissue typing, prophylaxis against viral and fungal infection, immunosuppressive drugs, and supportive care.


Hematopoietic Stem Cell Transplantation Emerging Drugs and Key Companies


  • IOMAB-B (CD45) (APAMISTAMAB-I-131): Actinium Pharmaceuticals
  • TRECONDI (TREOSULFAN): Medexus Pharmaceuticals /Medac Pharma
  • MOTIXAFORTIDE (BL-8040): BiolineRX, and others